Posts

TriGemX Bio plans SPAC merger to fund migraine drug development

on
On October 19, 2026, TriGemX Bio announced a definitive agreement to merge with TCGX Acquisition Corp. and become a publicly traded company. The proposed Nasdaq ticker is TGEM. The deal is expected to provide about $246 million in gross proceeds—$160 million from a private investment and roughly $86 million in TCGX trust funds, assuming no shareholder redemptions. The combined company is valued at about $600 million post-transaction. TriGemX plans to use the proceeds to advance elismetrep through Phase 3 trials for acute migraine, prepare an FDA application, study the drug for migraine prevention, and prepare for a possible U.S. launch. Elismetrep is an investigational oral TRPM8 channel blocker. Its first Phase 3 results are expected in mid-2027; the drug is not approved. The merger is expected to close in the first quarter of 2027, subject to shareholder approval and customary closing conditions. Sources: TriGemX Bio and TCGX Acquisition Corp. Announce Business Combinatio...

Veradermics reports another positive Phase 3 trial for oral minoxidil

on

Merck KGaA to acquire Silence Therapeutics for about $1.3 billion

on

AltruBio reports early ALTB-268 results in refractory ulcerative colitis

on

AstraZeneca previews four Phase III survival presentations at ESMO 2026

on

Disc Medicine’s bitopertin succeeds in Phase 3 after FDA rejection

on

Roche and Hansoh strike potential $15B-plus cancer-drug deal

on

AbbVie’s Crohn’s combo outperformed Skyrizi alone in Phase 2a trial

on

Gilead’s oral UC drug posts encouraging Phase 2 results

on

Novartis stops second phase of Fabhalta lupus-nephritis trial

on

Merck KGaA to acquire Silence Therapeutics for about $1.3 billion

on

Sanofi partners with ScionxBio on long-acting RNA

on

CHMP backs Lilly’s oral GLP-1 pill and five other new medicines

on